Abciximab inhibits not only Gp IIb/IIIa but also α IIb/β3 receptors (for vWF) on platelets, thereby decreasing aggregation through fibrinogen.[19] It is given intravenously and has shown its efficacy in reducing ischemic events in the management of acute coronary syndrome (ACS) and as adjunctive therapy during PCI,[6] but trials with orally administered Gp IIb/IIIa inhibitors have failed to demonstrate any benefit. This evidence concerns the gene ITGA2B and acute coronary syndrome.